Journal
TRANSLATIONAL RESEARCH
Volume 151, Issue 3, Pages 122-128Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2007.09.006
Keywords
-
Categories
Funding
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077769] Funding Source: NIH RePORTER
- National Institute on Minority Health and Health Disparities [P20MD002314] Funding Source: NIH RePORTER
- NHLBI NIH HHS [HL077769] Funding Source: Medline
- NIMHD NIH HHS [P20 MD002314-019002, P20 MD002314] Funding Source: Medline
Ask authors/readers for more resources
The activated leukocyte cell adhesion molecule (ALCAM/CD166/melanoma metastasis clone D (MEMD)) is an immunoglobulin superfamily cell adhesion molecule. It is expressed developmentally in cells of all 3 embryonic lineages. The ALCAM expression is limited to subsets of cells in most adult tissues. ALCAM is localized at intercellular junctions in epithelium presumably as part of the adhesive complex that maintains tissue architecture. Over the past decade, alterations in expression of ALCAM have been reported in several human tumors (melanoma, prostate cancer, breast cancer, colorectal carcinoma, bladder cancer, and esophageal squamous cell carcinoma). This review summarizes the current knowledge of the role of ALCAM in malignancies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
